| Kineta is a biopharmaceutical company focused on the discovery and development of disease-modifying therapies for neurodegenerative diseases. Co.'s primary program, YTX-7739, is in development for the potential treatment and disease modification of Parkinson's disease. YTX-7739 targets an enzyme known as stearoyl-CoA desaturase (SCD). Inhibition of SCD in multiple cellular systems, including patient-derived neurons, as well as in a mouse model of Parkinson's disease, has been demonstrated to reverse the toxicity of misfolded alpha-synuclein, a protein strongly associated with Parkinson's disease. The KA average annual return since 2016 is shown above.
The Average Annual Return on the KA average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KA average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KA average annual return calculation with any dividends reinvested as applicable (on ex-dates).